Latest Regeneron News & Updates

See the latest news and media coverage for Regeneron. We track all announcements, press releases, and industry mentions in real time, all in one place.

Regeneron

Biopharmaceutical company

regeneron.com

Headquarters: Tarrytown, United States
Company type: Public company
Number of employees: 15,000+
Industry: Pharmaceuticals

Last updated Today

Latest news about Regeneron

In short: Regeneron achieved strong Q1 2026 results driven by Dupixent growth, though shares faced pressure from a late-stage skin cancer trial miss.

Company announcements

July 30 Regeneron

Regeneron reported strong Q2 2026 financial results with 17% revenue growth

Revenues increased to $4.3 billion, driven by Dupixent and EYLEA HD sales. GAAP EPS was $12.23, non-GAAP EPS $14.29.

July 29 Regeneron

Regeneron mourns the passing of director Art Ryan

He served on the board for over two decades and was a trusted advisor.

June 22 Regeneron

Regeneron announces FDA and EMA accept cemdisiran submissions for gMG

NDA under Priority Review with action date November 2026; EU decision expected H2 2027. Cemdisiran could be first siRNA for gMG with subcutaneous dosing four times a year.

May 28 Regeneron

Regeneron's Ebola antibody recommended by WHO for investigational use

The antibody, maftivimab, has shown broad activity against Bundibugyo virus in vitro and will be evaluated in clinical trials.

Media coverage

July 31 Endpoints News

Regeneron, Sanofi tease potential expanded collaboration for Dupixent follow-ons

Regeneron & Sanofi discuss expanding partnership, potentially including Dupixent follow-ons. CEOs Schleifer & Garijo cite need to rebuild trust amid ongoing litigation.

July 30 BioSpace

Regeneron’s ‘aversion’ to M&A questioned as bumper Q2 builds war chest

Calls for Regeneron to step up dealmaking have intensified as the company has established an $18 billion cash pile and suffered clinical trial setbacks. Regeneron...

July 30 Yahoo Finance

Regeneron Q2 Earnings Beat, Sales Up on Dupixent & Eylea HD Strength

REGN's Q2 earnings and revenues beat estimates as robust Eylea HD demand and higher Dupixent profits...

July 30 Endpoints News

Takeda, Regeneron, Sanofi and Bristol Myers trim pipelines

Takeda, Regeneron, Sanofi and BMS trim pipelines in Q2 updates; BMS drops Ph3 prostate cancer degrader BMS-986365, Takeda cuts celiac drug TAK-101.

Never miss news about Regeneron

Track Regeneron and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Regeneron competitors & trending companies

Browse news for competitors to Regeneron and other trending companies.